Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.65 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.58 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.58 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815322 | 0.91 | LMNA (0.65) | KDRPDK1TRPV1GRM4LMNA | |
| SCHEMBL28875490 | 0.87 | KDR (0.57) | KDRPDK1TRPV1MEN1KMT2A | |
| SCHEMBL118026 | 0.86 | KDR (1.00) | KDRPDK1TRPV1GRM4CA1 | |
| SCHEMBL29364392 | 0.86 | KDR (1.00) | KDRPDK1TRPV1GRM4CA1 | |
| SCHEMBL9835641 | 0.85 | KDR (0.78) | KDRPDK1TRPV1GRM4LMNA | |
| SCHEMBL2329430 | 0.85 | KDR (0.78) | KDRPDK1TRPV1GRM4LMNA | |
| SCHEMBL21879897 | 0.85 | ALDH1A1 (0.59) | KDRPDK1TRPV1GAASMN1; SMN2 | |
| SCHEMBL10885507 | 0.85 | KDR (0.78) | KDRPDK1TRPV1GRM4LMNA | |
| SCHEMBL2350751 | 0.84 | KDR (0.68) | KDRPDK1GRM4LMNAMEN1 | |
| SCHEMBL202023 | 0.84 | KDR (0.68) | KDRPDK1TRPV1GRM4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241427-A | Method for comprehensively and efficiently synthesizing anticancer drug regorafenib | 董帅圻 | 2025-01-03 | — | — | CN | claimed |
| US-12623942-B2 | Method for extracting salts and temperature- regenerated extracting composition | ADIONICS (FR) | 2026-05-12 | — | — | US | disclosed |
| CN-119241427-A | Method for comprehensively and efficiently synthesizing anticancer drug regorafenib | 董帅圻 | 2025-01-03 | — | — | CN | disclosed |
| CN-113292128-B | Apparatus and method for desalting water by thermal deionization and liquid phase ion extraction | 艾迪奥尼克斯公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230382775-A1 | METHOD FOR EXTRACTING SALTS AND TEMPERATURE-REGENERATED EXTRACTING COMPOSITION | ADIONICS (FR) | 2023-11-30 | — | — | US | disclosed |
| US-11772997-B2 | Method for extracting salts and temperature-regenerated extracting composition | ADIONICS (FR) | 2023-10-03 | — | — | US | disclosed |
| CN-116791107-A | Method for synthesizing 4-chloro-3-trifluoromethyl aniline by electrochemical trifluoromethyl | 瑞博(苏州)制药有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11731933-B2 | Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid | ADIONICS (FR) | 2023-08-22 | — | — | US | disclosed |
| CN-109641160-B | Method for extracting salt and temperature-regenerated extraction composition | 艾迪奥尼克斯公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210355076-A1 | DEVICE AND METHOD FOR THE DESALINATION OF WATER BY MEANS OF THERMAL DEIONISATION AND LIQUID-PHASE ION EXTRACTION LIQUID | ADIONICS (FR) | 2021-11-18 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2007070947-A1 | ANTIBACTERIAL AGENTS | ALCHEMIA LTD (AU) | 2007-06-28 | — | — | WO | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731933-B2 | Device and method for the desalination of water by means of thermal deionisation and liquid-phase ion extraction liquid | AQP3, AQP1, AQP4 | KDR 863/4885PDK1 3510/4885TRPV1 149/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | KDR 1285/4885PDK1 2020/4885TRPV1 102/4885 |
| US-20210355076-A1 | DEVICE AND METHOD FOR THE DESALINATION OF WATER BY MEANS OF THERMAL DEIONISATION AND LIQUID-PHASE ION EXTRACTION LIQUID | AQP3, AQP1, AQP4 | KDR 863/4885PDK1 3510/4885TRPV1 149/4885 |
| US-12623942-B2 | Method for extracting salts and temperature- regenerated extracting composition | POLQ, NONO, AQP3 | KDR 748/4885PDK1 2806/4885TRPV1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.